Comprehensive notes on Dopaminergic Pharmacology, PD, AD, and ATTR (Lecture Transcript)

Exam logistics and course structure

  • Virtual discussions only: no in-person requirement for discussion; assignments and discussions are conducted virtually.
  • Exam scope: material discussed up to today is included in Friday’s exam; any material covered until end of today will be on the exam.
  • Emphasis on integration of pharmacology concepts with clinical relevance and exam-style questioning.

Adrenergic antagonists: overview and key examples

  • Block adrenergic receptors; two main categories discussed:
    • Quinazoline-based drugs (alpha-1 blockers): structure includes quinazoline rings; activity and half-life depend on side chains.
    • Alpha-1 blockers usage: hypertension and benign prostatic hyperplasia (BPH).
    • For patients with both hypertension and BPH, these blockers are effective due to targeting alpha-1 receptors in vasculature and prostate.
    • For patients with hypertension only, selective alpha-1 blockers are preferred to avoid vascular issues when no prostate problem is present.
  • Beta blockers: molecules that block beta-adrenergic receptors; classic framework described as an aryl-oxy-alkyl amine scaffold (often depicted as a propanolamine core with an aryl group and ether linkage).
    • Classic examples: propranolol and nadolol.
    • Commonly used beta-blockers that end with “-olol” (e.g., atenolol, bisoprolol) and their CNS side-effect profiles differ by polarity.
    • Polar vs. nonpolar: nadolol is more polar than propranolol (extra hydroxylation increases polarity).
    • CNS side effects: atenolol tends to have fewer CNS adverse effects than propranolol due to higher polarity and reduced brain penetration.
    • Exam tip: given two beta blockers, determine which has less CNS side effects by assessing polarity; more polar = fewer CNS effects.

Dopaminergic system and Parkinson’s disease: basic framework

  • Dopamine is a catecholamine CNS neurotransmitter that governs emotion, movement, and reward.
  • Dopamine’s relation to diseases:
    • Parkinson’s disease (PD): characterized by insufficient dopaminergic signaling due to loss of dopaminergic neurons; therapeutic goal is to increase dopamine or its signaling.
    • Depression and psychosis involve dopamine dysregulation in opposite directions, illustrating the importance of the right dopamine levels.
  • Dopamine biosynthesis and metabolism (simplified):
    • Tyrosine → (tyrosine hydroxylase) → L-DOPA → (AADC/DOPA decarboxylase) → Dopamine → (DBH) → Norepinephrine → (PNMT) → Epinephrine.
    • Dopamine alone does not cross the blood–brain barrier (BBB); L-DOPA does via active transport, acting as a prodrug to increase brain dopamine levels.
    • In the brain, dopamine is produced in presynaptic neurons, released, and binds to postsynaptic dopamine receptors (GPCRs). There are also presynaptic D2 autoreceptors that regulate dopamine release.
  • Dopamine reuptake and metabolism:
    • Dopamine transporter (DAT) reuptakes dopamine from the synaptic cleft back into the presynaptic neuron.
    • Psychostimulants (e.g., amphetamine) block DAT, increasing extracellular dopamine and producing rewarding effects.
    • Metabolism of dopamine: MAO and COMT convert dopamine to metabolites such as DOPAC and homovanillic acid (HVA).
    • End products for clinical testing:
    • Dopamine metabolism end products: HVA (homovanillic acid).
    • Norepinephrine/epinephrine metabolism end products: VMA (vanillylmandelic acid).
  • Clinical relevance of metabolites and testing:
    • Accumulation of HVA in CSF and brain reflects dopaminergic neuronal activity; increased HVA can occur with drugs that raise dopamine turnover (e.g., antipsychotics).
    • Urinary VMA and HVA testing (e.g., Mayo Clinic reference ranges) aids in screening for catecholamine-secreting tumors (neuroblastoma, pheochromocytoma) and monitoring treatment effects.
    • Key clinical note: MAO deficiencies or dopamine β-hydroxylase deficiencies can alter HVA levels, illustrating genetics’ impact on metabolism.
  • Dopaminergic receptors and auto-regulation:
    • Postsynaptic dopamine receptors: five GPCR subtypes, mediating movement and reward pathways.
    • D2 autoreceptor: presynaptic receptor that, when activated, reduces dopamine release; antagonism can increase dopamine availability.
  • Parkinson’s disease: pathophysiology and therapeutic strategy (chemistry focus)
    • PD is associated with a loss of ~75% of dopaminergic neurons in the substantia nigra; this depletion disrupts motor control.
    • Treatment approach is to raise brain dopamine levels or reduce its metabolism, because a cure (cell replacement) is not yet available.
    • Dopaminergic therapy includes L-DOPA administration, metabolic inhibitors, and strategies to increase brain delivery of dopamine.
    • A long-term goal involves regenerating dopaminergic neurons or inducing brain plasticity to compensate for neuron loss.
  • Historical anecdote and implications for clinical practice:
    • The MPTP story (Barry et al., 1980s) demonstrated that a toxin can selectively kill dopaminergic neurons, producing PD-like symptoms. MAO-B inhibitors can mitigate MPTP’s toxic effects by blocking conversion to MPP+.
    • The MPTP incident underscored the importance of understanding metabolic activation and enzyme selectivity in PD management.

Levodopa (L-DOPA) therapy and periphery metabolism: pharmacokinetics and strategies to improve brain delivery

  • L-DOPA as a prodrug of dopamine:
    • Dopamine itself does not cross the BBB; L-DOPA crosses via amino acid transporters and is converted to dopamine in the brain.
    • L-DOPA has very poor oral bioavailability when given alone due to rapid peripheral metabolism and transport limitations.
  • Peripheral metabolism and limitations:
    • Step 1: AADC (aromatic L-amino acid decarboxylase) converts L-DOPA to dopamine in the periphery, causing peripheral dopaminergic side effects (e.g., hypertension).
    • Step 2: COMT (catechol-O-methyltransferase) can methylate L-DOPA and its metabolites, reducing brain delivery.
    • Step 3: MAO (monoamine oxidase) and COMT in the gut metabolize dopamine and L-DOPA-derived products, further diminishing central availability.
    • If COMT and MAO activities in periphery or gut are high, L-DOPA’s brain delivery is severely limited, and peripheral side effects increase.
  • Rationale for combination therapy (triple therapy):
    • Block peripheral decarboxylation to dopamine with AADC inhibitor (carbidopa); this increases L-DOPA availability for the brain and reduces peripheral side effects.
    • Inhibit peripheral COMT with a COMT inhibitor (tolcapone or entacapone) to reduce peripheral L-DOPA metabolism and increase brain delivery; note: tolcapone crosses the BBB and has hepatotoxicity concerns; entacapone is peripheral and has less hepatotoxicity.
    • Inhibit MAO to reduce non-synaptic metabolism of dopamine; MAO inhibitors can prolong L-DOPA’s half-life and availability, but require careful monitoring due to cheese- and tyramine-related interactions.
  • Key drug examples and properties:
    • Carbidopa: an AADC inhibitor that does not cross the BBB; prevents peripheral conversion of L-DOPA to dopamine, allowing more L-DOPA to reach the brain.
    • Tolcapone: a CNS- and periphery-penetrant COMT inhibitor; high efficacy but risk of hepatotoxicity.
    • Entacapone: a peripheral COMT inhibitor with lower hepatotoxicity; does not cross the BBB; used in triple therapy to improve central delivery of L-DOPA.
    • Rasagiline and Selegiline (MAO-B inhibitors): used to decrease dopamine metabolism, supporting increased synaptic dopamine levels; dose-dependent selectivity for MAO-B with potential cheese effect at higher doses due to dual MAO inhibition.
  • Cheeses, tyramine, and the “cheese effect” with MAO inhibitors:
    • Tyramine is a monoamine found in wine and cheese; it is a substrate for MAO-A and MAO-B but not for COMT.
    • In the presence of nonselective MAO inhibitors, dietary tyramine can cause hypertensive crisis due to excessive peripheral monoamine activity.
    • Selective MAO-B inhibitors at low doses reduce tyramine risk, but high-dose regimens may lose selectivity and approach MAO-A inhibition.
  • Selegiline and its metabolites:
    • Selegiline is a selective MAO-B inhibitor at low doses; it reduces dopamine metabolism and can lower the required L-DOPA dose.
    • At higher doses, selectivity can be lost, leading to the cheese effect risk.
    • Selegiline can metabolize to amphetamine and methamphetamine metabolites; the L- and D-enantiomer forms have different activities, with the therapeutic ADHD drug being the dextro (D) enantiomer and the methamphetamine derived from Selegiline metabolism associated with abuse potential.
    • There are contemporary discussions and cautionary stories about misuse or misinterpretation of drug metabolites in drug testing.
  • Rasagiline specifics:
    • Rasagiline is a selective MAO-B inhibitor with a different safety and efficacy profile compared to selegiline; its metabolism involves alkylation, oxidation, and phase II conjugation (glucuronidation).
  • Clinical practice and exam-oriented insights:
    • In exams, be prepared to compare beta-blockers’ CNS effects by polarity. For L-DOPA therapy, explain why combining carbidopa with L-DOPA improves brain delivery and reduces peripheral toxicity, and why adding entacapone or tolcapone helps further optimize central dopamine levels.
    • Understand the cheese effect and tyramine interactions with MAO inhibitors, and how selective MAO-B inhibitors minimize risk at low doses but may become nonselective at higher doses.
  • Historical context and therapeutic advances:
    • L-DOPA remains the cornerstone of symptomatic PD treatment; other strategies aim to prolong L-DOPA’s effect and increase brain delivery.
    • Emerging approaches target neuroprotection, gene therapy, and potential dopamine neuron replacement in the long term; however, current treatments are primarily symptomatic.

Dopaminergic agonists and alternative strategies

  • Direct dopamine receptor agonists:
    • Ergot derivatives (ergot-type dopamine agonists): natural product alkaloids that activate dopamine receptors; include complex structures.
    • Non-ergot derivatives: apomorphine, pramipexol, ropinirole (described as ramipin? and dropanol in the lecture).
  • Role of agonists: can activate remaining dopaminergic receptors when endogenous dopamine is low; used for patients who respond inadequately to L-DOPA.

Alzheimer’s disease: pathology and pharmacotherapy (brief overview linked to memory and lifestyle factors)

  • Pathophysiology overview:
    • Alzheimer’s disease (AD) is characterized by progressive memory loss and cognitive decline; brain atrophy with enlarged sulci and reduced neuronal count.
    • Key pathological features include amyloid-beta plaques and neurofibrillary tangles; amyloid precursor protein (APP) is cleaved by secretases to yield beta-amyloid peptides (notably Aβ42) that aggregate into plaques.
  • Therapeutic approaches under discussion/practice:
    • Secretase inhibitors (beta- and gamma-secretase inhibitors) to reduce production of beta-amyloid peptides.
    • Aggregation inhibitors and antibodies targeting monomeric or oligomeric amyloid-beta to prevent plaque formation or promote clearance.
    • Immunotherapy: antibodies against amyloid-beta oligomers/plaque; discussed as a possible intervention with limited success and high cost.
    • Cholinesterase inhibitors (e.g., rivastigmine, an arylcarbamate) to enhance cholinergic signaling and provide symptomatic relief.
  • Imaging and early detection:
    • Fluor-beta-bear (a radioligand, e.g., florbetapir) PET imaging agent used to visualize amyloid plaques in the brain; helps with diagnosis and understanding disease progression.
    • The positive imaging indicates amyloid burden and informs management decisions.
  • Lifestyle and neuroprotection concepts:
    • Still Alice, Lisa Genova’s work and related TED talks emphasize prevention via sleep, exercise, and mental stimulation.
    • Neuroplasticity and cognitive reserve: engagement in mentally stimulating activities supports brain resilience.
  • Practical takeaways:
    • Early detection and lifestyle interventions may help delay progression; there is currently no cure, and therapies focus on symptomatic relief and slowing progression.

Transthyretin (TTR) amyloidosis: protein misfolding, stabilization, and therapeutic breakthroughs

  • Biology of TTR:
    • Transthyretin (TTR) is a tetrameric protein produced mainly by the liver and brain; it transports thyroid hormones (e.g., thyroxine) and retinol-binding protein with vitamin A transport implications.
    • In the brain, TTR helps transport thyroid hormone and may play a role in amyloid deposition; misfolding of TTR can cause systemic amyloidoses including polyneuropathy and cardiomyopathy.
  • TTR and amyloid formation:
    • The disease can arise from TTR tetramer dissociation into monomers that misfold and aggregate into amyloid plaques; these deposits cause polyneuropathy and heart failure, leading to severe morbidity.
  • Stabilizers of TTR: a drug discovery story and structure-based design
    • Rationale: stabilizing the TTR tetramer prevents dissociation and subsequent amyloid formation.
    • Tafamidis (Pfizer) and AG10 (agatian/gene name AG10; sometimes referred to as AG10 or AG-10) are stabilizers.
    • Crystal structures (2013–2015) showed how stabilizers bind in the TTR pocket between dimers, stabilizing the tetramer.
    • Pfizer’s tafamidis (brand name Tafamidé/Vyndamax) binds in the pocket and forms interactions that stabilize the tetramer; its efficacy is modest (about 50% stabilization in some models).
    • AG10 (agiton/agatian) was designed to more closely mimic the T119M variant and stabilize the tetramer more effectively; in early structural work (2013), AG10 appeared to stabilize >95% of TTR in vitro, suggesting a stronger stabilization effect than tafamidis.
  • Clinical development and market dynamics (as described in the lecture):
    • The story highlights a long developmental timeline (2008–2018) culminating in public funding and eventual regulatory approval; the speaker emphasizes the impact of company strategies and market size considerations on drug development and adoption.
    • Tafamidis received regulatory approvals for transthyretin amyloid polyneuropathy and cardiomyopathy indications; AG10 story represents a parallel development with the potential for broader stabilization and possibly improved patient outcomes.
  • Structural insights and comparisons:
    • Stabilizers bind in the TTR pocket at the dimer interface; proper binding promotes salt-bridge formation and hydrogen bonding, reinforcing tetramer stability.
    • AG10’s design aims to replicate the stabilizing effects of the protective TTR mutation T119M (which creates an extra hydrogen bond and stronger interface), potentially translating to longer-lived stability and improved clinical outcomes.
    • The Pfizer molecule (tafamidis) forms fewer stabilizing interactions in the bottom part of the pocket, whereas AG10 forms robust interactions with both the top (lysine residues via salt bridges) and bottom (serine residues via hydrogen bonds) regions, yielding stronger overall stabilization.
  • Practical implications and future directions:
    • A stable TTR tetramer could theoretically prevent amyloid deposition and slow disease progression; the best stabilization strategy may depend on individual genetics and the specific TTR mutations.
    • The field continues to explore whether stabilization alone suffices or whether additional approaches (gene therapy, antisense oligonucleotides, or combination therapies) are needed for optimal outcomes.

Closing reflections and exam-ready takeaways

  • The lecture emphasizes the integration of chemistry with pharmacology and clinical practice:
    • Understanding how drug structure influences receptor selectivity, blood–brain barrier penetration, and side-effect profiles is key for predicting clinical outcomes.
    • Pharmacokinetics and pharmacodynamics are tightly linked to the molecular features of each drug (polarity, transporter usage, metabolic enzymes).
  • Important exam-style concepts you should be able to articulate:
    • Compare propranolol and atenolol in terms of CNS penetration and why one may have fewer CNS side effects.
    • Explain why L-DOPA is given with carbidopa and sometimes with entacapone or tolcapone, including the roles of AADC, COMT, and MAO in peripheral and central metabolism.
    • Describe the cheese effect and tyramine metabolism in the context of MAO inhibitors; explain why selectivity matters at different dose levels.
    • Outline the MPTP paradigm and its implications for PD research and treatment strategies.
    • Summarize the strategies for treating Alzheimer’s disease (secretase inhibitors, aggregation inhibitors, antibodies, and cholinesterase inhibitors like rivastigmine) and the rationale behind imaging with amyloid PET ligands.
    • Understand the concept of TTR as a stabilizer target in amyloidosis and how pocket-binding stabilizers (tafamidis vs AG10) differ in their binding interactions and stabilization potential.
  • Practical mindset:
    • Always relate a drug’s chemical features to its pharmacologic and clinical consequences.
    • Be prepared to discuss real-world considerations (drug interactions, dietary restrictions with MAO inhibitors, and cost/availability issues) that influence treatment choices.
  • Final note from the instructor:
    • The field is rapidly evolving; staying updated with new therapeutic approaches and imaging modalities is essential for a practicing pharmacist or clinician.